New data backs promise of long-acting Sanofi insulin

The long-acting insulin, known as U300, requires less frequent or lower dosing than Lantus and offers a more consistent insulin release.

 

An improved version of Sanofi’s Lantus diabetes drug is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events, new late-stage trial data showed on Tuesday.

The treatment is one of several drugs Sanofi is betting on to defend its No.2 spot on the world’s $42 billion diabetes market as its star product Lantus, the world’s most prescribed insulin, will lose patent protection by 2015.

The long-acting insulin, known as U300, requires  ..

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s